Choroid plexus tumors are relatively rare lesions, accounting for fewer than 1% of intracranial neoplasms (1, 2). They may exhibit a wide spectrum of histologic patterns, including acinar (3, 4), mucussecreting (5, 6), oncocytic (7,8), pigmented (9, 10), tubular (11), and metaplastic (5, 12, 13) variants. Distinguishing these tumors from metastatic carcinomas, a matter of considerable therapeutic and prognostic significance, therefore can be problematic. A number of potential immunohistochemical markers for choroid plexus tumors, including glial fibrillary acidic protein (14 -25), S-100 protein (14 -17, 21, 23), vimentin (14 -17), cytokeratin (CK) (14 -20, 22), non-CK epithelial markers (16, 17, 21, 26), carcinoembryonic antigen (14, 15, 18, 21), neuronal markers (15, 21, 27), and transthyretin (14, 21, 23, 28, 29), have been evaluated; however, their utility has been limited by a lack of specificity and by the conflicting results yielded by these studies. Recently, the evaluation of the coordinate expression of CK7 and CK20 has been shown to be of use in distinguishing primary from metastatic lesions in a number of anatomic sites (30 -32). The CK7/CK20 immunophenotypes of a large number of neoplasms have been characterized (Table 1). Moreover, it has been shown that these lesions retain their CK7/CK20 immunophenotype in metastatic locations, including the brain (33).We examined 35 choroid plexus tumors with a panel of antibodies, including CK7 and CK20, to determine their immunophenotype. The potential diagnostic implications of these findings are discussed.